p53 Inhibition by the LANA protein of KSHV protects against cell death

Nature

Volumn 402, Issue 6764, 1999, Pages 889-894

  Friborg Jr , Jacques ^a   Kong, Wing Pul ^a   Hottlger, Michael O ^a,b   Nabel, Gary J ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS ANTIGEN; ONCOPROTEIN; PROTEIN P53; VIRUS ANTIGEN; VIRUS PROTEIN;

ANIMAL CELL; ARTICLE; CARCINOGENESIS; CELL DEATH; CELL TRANSFORMATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 8; IMMUNOGENICITY; KAPOSI SARCOMA; LYMPHOPROLIFERATIVE DISEASE; NONHUMAN; OPEN READING FRAME; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS GENE; VIRUS LATENCY;

ANTIGENS, VIRAL; APOPTOSIS; CELL LINE; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; CELL TRANSFORMATION, VIRAL; CHLORAMPHENICOL O-ACETYLTRANSFERASE; GENE EXPRESSION REGULATION, VIRAL; HERPESVIRUS 8, HUMAN; HUMANS; JURKAT CELLS; NUCLEAR PROTEINS; PROTEIN BINDING; SARCOMA, KAPOSI; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; VIRAL PROTEINS;

ANIMALIA; DNA VIRUSES; HERPESVIRIDAE; HERPESVIRUS 8; HUMAN HERPESVIRUS 8; LANA; RNA VIRUSES;

EID: 0033599006     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/47266     Document Type: Article

References (30)

1. Chang, Y. et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266, 1865-1869 (1994).
2. Moore, P. S. & Chang, Y. Detection of herpes-like virus DNA sequences in Kaposi's sarcoma in patients with and without HIV infection. N. Engl. J. Med. 332, 1181-1185 (1995).
3. Cesarman, E., Chang, Y., Moore, P. S., Said, J. W. & Knowles, D. M. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl. J. Med. 332, 1136-1191 (1995).
4. Neipel, F., Albrecht, J.-C. & Fleckenstein, B. Cell-homologous genes in the Kaposi's sarcoma-associated rhadinovirus human herpesvirus 8: determinants of its pathogenecity? J. Virol. 71, 4187-4192 (1997).
5. Sarid, R., Flore, O., Bohenzky, R. A., Chang, Y. & Moore, P. S. Transcription mapping of the Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) genome in a body. J. Virol. 72, 1005-1012 (1998).
6. Rainbow, L. et al. The 222-to 234-kilodalton latent nuclear protein (LNA) of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) is encoded by orf73 and is a component of the latency-associated nuclear antigen. J. Virol. 71, 5915-5921 (1997).
7. Kedes, D. H., Lagunoff, M., Renne, R. & Ganem, D. Identification of the gene encoding the major latency-associated nuclear antigen of the Kaposi's sarcoma-associated herpesvirus. J. Clin. Invest. 100, 2606-2610 (1997).
8. Gao, S. J. et al. Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma. N. Engl. J. Med. 335, 233-241 (1996).
9. Kedes, D. H. et al. The seroepidemiology of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus): distribution of infection in KS risk groups and evidence for sexual transmission. Nature Med. 2, 918-924 (1996).
10. Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell 88, 323-331 (1997).
11. Hollstein, M., Sidransky, D., Vogelstein, B. & Harris, C. C. p53 mutations in human cancers. Science 253, 49-53 (1991).
12. Ko, L. J. & Prives, C. p53: puzzle and paradigm. Genes Dev. 10, 1054-1072 (1996).
13. Dobner, T., Horikoshi, N., Rubenwolf, S. & Shenk, T. Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor. Science 272, 1470-1473 (1996).
14. Werness, B. A., Levine, A. J. & Howley, P. M. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248, 76-79 (1990).
15. Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J. & Howley, P. M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63, 1129-1136 (1990).
16. Chen, X., Ko, L. J., Jayaraman, L. & Prives, C. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev. 10, 2438-2451 (1996).
17. Lill, N. L., Grossman, S. R., Ginsberg, D., DeCaprio, J. & Livingston, D. M. Binding and modulation of p53 by p300/CBP coactivators. Nature 387, 823-827 (1997).
18. Li, R. et al. Mutant p53 protein expression interferes with p53-independent apoptotic pathways. Oncogene 16, 3269-3277 (1998).
19. Moore, P. S. & Chang, Y. Antiviral activity of tumor-suppressor pathways clues from molecular piracy by KSHV, Trends Genet. 4, 144-150 (1998).
20. Chang, Y. et al. Cyclin encoded by KS herpesvirus. Nature 382, 410 (1996).
21. Ballestas, M. E., Chatis, P. A. & Kaye, K. M. Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen. Science 284, 641-644 (1999).
22. Li, J. J. et al. Expression and mulation of the tumor suppressor gene p53 in AIDS-associated Kaposi's sarcoma. Am. J. Dermatopathol. 19, 373-378 (1979).
23. Noel, J.-C. p53 protein and Kaposi's sarcoma. Am. J. Dermatopathol. 19, 322-322 (1997).
24. Kern, S. A. et al. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256, 827-830 (1992).
25. Hottiger, M. O. & Nabel, G. J. Interaction of human immunodeficiency virus type 1 Tat with the transcriptional coactivators p300 and CREB binding protein. J. Virol. 72, 8252-8256 (1998).
26. Felzien, L. K. et al. HIV transcriptional activation by the accessory protein, VPR, is mediated by the p300 co-activator. Proc. Natl Acad. Sci. USA 95, 5281-5286 (1998).
27. Emami, K. H. & Carey, M. A synergistic increase in potency of a multimerized VP16 transcriptional activation domain. EMBO J. 11, 5005-5012 (1992).
28. Yang, S. et al. Generation of retroviral vector for clinical studies using transient transfection. Hum. Gene Ther. 10, 123-132 (1990).
29. Chen, C. & Okayama, H. High-efficiency transformation of mammalian cells by plasmid DNA. Mol. Cell. Biol. 7, 2743-2752 (1987).
30. Leung, K. & Nabel, G. J. HTLV-1 transactivator induces interleukin-2 receptor expression through an NF-kB-like factor. Nature 333, 776-778 (1988).